Fortrea Holdings Inc 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June30, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number 001-41704 FORTREA HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware92-2796441(I.R.S. Employer (Address of principal executive offices)(Zip Code) (Registrant's telephone number, including area code)(877) 495-0816 Securities registered pursuant to Section 12(b) of the Act. Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) hasbeen subject to such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit and post such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one): If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNo The registrant had outstanding 95.1 million shares of common stock as of July27, 2026. INDEX PART I. FINANCIAL INFORMATION Financial Statements (unaudited)Condensed Consolidated Balance SheetsJune30, 2026 and December31, 2025Condensed Consolidated Statements of OperationsThree and six months ended June30, 2026 and 2025Condensed Consolidated Statements of Comprehensive LossThree and six months ended June30, 2026 and 2025Condensed ConsolidatedStatements of Changes in EquityThree and six months ended June30, 2026 and 2025Condensed Consolidated Statements of Cash FlowsSix months ended June30, 2026 and 2025Notes to Unaudited Condensed Consolidated Financial StatementsManagement’s Discussion and Analysis of Financial Condition and Results of OperationsQuantitative and Qualitative Disclosures About Market RiskControls and Procedures Item 1. PART II. OTHER INFORMATION Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.Exhibits FORTREA HOLDINGS INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in millions)(unaudited) FORTREA HOLDINGS INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in millions) (unaudited) FORTREA HOLDINGS INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(dollars and shares in millions, except per share data) 1.BASIS OF FINANCIAL STATEMENT PRESENTATION Description of Business Fortrea Holdings Inc. (“Fortrea” or the “Company”), a Delaware corporation incorporated on January 31, 2023, is a leading globalcontract research organization (“CRO”) providing biopharmaceutical product and medical device development solutions topharmaceutical, biotechnology and medical device customers. The Company offers customers highly flexible delivery models that includeFull Service, Functional Service Provider, and Hybrid Service structures. The Company has a rich history of providing clinicaldevelopment services for more than 30 years across more than 20 therapeutic areas. The Company leverages its global scale, clinical datainsights, scientific and therapeutic expertise, technology innovation, industry network and decades of experience as a standalone companyand as a business unit prior to its spin-off from Labcorp Holdings Inc. to deliver tailored solutions to its customers. With what theCompany believes is a distinctive market offering, Fortrea meets growing global demand for clinical development services. The Companyhas established access to all key markets worldwide through a strategic footprint of primary office locations in five countries (the UnitedStates, the United Kingdom, China, India and Japan) with field operations in other jurisdictions worldwide. On March 9, 2024, the Company, together with its wholly-owned subsidiary, Fortrea Inc., entered into an Asset Purchase Agreementwith Endeavor Buyer LLC, an affiliate of Arsenal Capital Partner